NeuroSense Therapeutics

NeuroSense Therapeutics

生物技术研究

Cambridge,Massachusetts 9,209 位关注者

Creatively and diligently moving fast towards an effective treatment for people with ALS.

关于我们

Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally. $NRSN

网站
https://www.neurosense-tx.com/
所属行业
生物技术研究
规模
11-50 人
总部
Cambridge,Massachusetts
类型
上市公司
创立
2017
领域
Drug Development、ALS、MND、Lou Gehrig's Disease、CNS、Biopharmaceuticals、Neurodegenerative Diseases、Parkinson's Disease、Alzheimer's disease和Novel treatment

地点

NeuroSense Therapeutics员工

动态

相似主页

查看职位

融资